EP Patent

EP0122036A1 — Powdery pharmaceutical composition for nasal administration

Assigned to Teijin Ltd · Expires 1984-10-17 · 42y expired

What this patent protects

What is provided by this invention is a powdery pharmaceutical composition for nasal administration comprising physiologically active polypeptide or its derivative such as calcitonin, insulin, etc. and a water-absorbing and water-insoluble base. The pharmaceutical composition all…

USPTO Abstract

What is provided by this invention is a powdery pharmaceutical composition for nasal administration comprising physiologically active polypeptide or its derivative such as calcitonin, insulin, etc. and a water-absorbing and water-insoluble base. The pharmaceutical composition allows polypeptide or its derivative to be efficiently absorbed through the nasal macous membrane when it is nasally administered.

Drugs covered by this patent

Patent Metadata

Patent number
EP0122036A1
Jurisdiction
EP
Classification
—
Expires
1984-10-17
Drug substance claim
No
Drug product claim
No
Assignee
Teijin Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.